Anacor Pharmaceuticals Files For IPO

Palo Alto-based Anacor Pharmaceuticals filed for an IPO Friday evening, saying in a filing with the SEC that it is looking to raise up to $57.5M in an IPo on the Nasdaq Global Market. The firm is looking to list as "ANAC." The IPO is being underwritten by Morgan Stanley, Cowen and Company, Pacific Growth Equities, and Needham & Company. Anacor develops small-molecule therapeutics initially targeted at treating fungal, bacterial and inflammatory diseases. The firm is venture backed by Rho Ventures, Venrock Associates, Care Capital Investments, and Aberdare Ventures, among others.